Webinar - Managing AF in primary care: Practical considerations
In this 50-minute webinar recording, Dr Jim Moore discusses the practical considerations of managing atrial fibrillation in primary care, addressing some key topics:
- The use of anticoagulation in NVAF; understanding why certain patients should be anticoagulated and the issue with under-treatment
- The treatment options for anticoagulation in patients with NVAF; including reviewing efficacy and safety profiles of DOACs and understanding the considerations for more complex cases
- Exploring the practicalities of DOAC prescribing for managing stroke prevention in AF
This webinar was recorded in November 2019. This was a promotional webinar intended for UK Healthcare Professionals that was organised and fully funded by Bayer plc
We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.
To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget
Reporting adverse events and quality complaints
This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email: email@example.com
Further information is available on the "contact" tab at www.bayer.co.uk.